Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events (irAEs). We conducted an observational retrospective/prospective study on patients with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Argnani, Lisa, Casadei, Beatrice, Pelusi, Carla, Lo Preiato, Valentina, Pagotto, Uberto, Bertoni, Francesco, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810842/
https://www.ncbi.nlm.nih.gov/pubmed/35110658
http://dx.doi.org/10.1038/s41598-022-05861-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810842/
https://www.ncbi.nlm.nih.gov/pubmed/35110658
http://dx.doi.org/10.1038/s41598-022-05861-0

Ejemplares similares